Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Bortezomib based therapies for myeloma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 02.07.09
Views: 14575

Dr Paul Richardson - Hematologic Oncology Dept, Dana-Farber Cancer Institute

Dr Paul Richardson, Hematologic Oncology Dept, Dana-Farber Cancer Institute, speaking at ASCO 2009 about Bortezomib based therapies in relapsed and refractory myeloma. Tanespimycin with bortezomib (some neuroprotection found). HSP-90 inhibtion is an important therapeutic target. Also covers his highlights from the conference. Also lenalidomide with bortezomib and dexamethasone (RVD platform)

Related videos

follow us

WIN 2020

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation